BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

BTLA inhibitor (JS004):200mg, intravenous infusion , d1, Q3W;

Toripalimab:240mg,intravenous infusion, d1, Q3W;

Paclitaxel, 175mg/m2, intravenous infusion, d1, Q3W; Cisplatin, 75mg/m2, intravenous infusion, d1, Q3W;